Clinical Trial Update: A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia. [Phase 2]

View source ↗

Summary

Phase 2 study of the farnesyl transferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. The trial status is listed as com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Leukemia, Nonlymphocytic, Acute | Phase 2 | Status: COMPLETED